Silk Road Medical Inc . (NASDAQ:SILK) reported Q2 EPS of ($0.44), in-line with the analyst estimate of ($0.44). Revenue for the quarter came in at $33.2 million versus the consensus estimate of $31.04 million.
“We achieved several important milestones in the second quarter. We expanded our FDA label and Medicare coverage for the use of TCAR in standard surgical risk patients, formally initiated our ROADSTER 3 post approval study, and secured access to a $250 million debt facility,” said Erica Rogers (NYSE:ROG), CEO of Silk Road Medical. “We also gained meaningful market share through strong physician utilization as we continue to establish TCAR as the minimally-invasive standard of care in stroke prevention, evidenced by recently eclipsing 50,000 global TCAR procedures.”